A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn D. Crater, David L. Bourdet, Nathan D. Pfeifer, Jacky Woo, Elad Kaufman, David A. Lombardi, Emily Y. Weng, Tuan Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Article number2100673
JournalEuropean Respiratory Journal
Volume58
Issue number4
DOIs
Publication statusPublished - 1 Oct 2021

Cite this